The Phase 2 results emphasize treatment tolerability and adherence, two factors that often determine whether obesity therapies succeed in real-world use.
Zealand Pharma has reported positive Phase 2 results for petrelintide, an investigational once-weekly amylin analog designed to improve the long-term treatment experience for people living with overweight or obesity. The Phase 2 trial evaluated both weight-loss outcomes and how well patients were able to remain on therapy over time.
The ZUPREME-1 trial included 493 participants with overweight or obesity and found that patients receiving the highest dose achieved 10.7% mean weight loss at 42 weeks, compared with 1.7% in the placebo group.
While weight loss was clinically meaningful, the company emphasized another outcome: tolerability and treatment persistence.
Focus on the Patient Experience
The trial results suggest petrelintide may offer a treatment profile that patients can stay on over time. Several outcomes support this focus on long-term treatment adherence.
Key findings include:
- Placebo-like tolerability, with safety outcomes similar to placebo.
- No cases of vomiting in the highest-dose group.
- Discontinuation due to adverse events of 4.8%, comparable to 4.9% in the placebo arm.
- 98% of participants successfully escalated to the target dose, suggesting strong adherence to the treatment regimen.
Most reported side effects were mild gastrointestinal events, and nausea largely subsided once patients reached their maintenance dose.
This emphasis reflects a broader challenge in obesity care: many currently available therapies demonstrate strong efficacy in clinical trials but see high discontinuation rates in real-world use, often due to tolerability issues.
Petrelintide Summary
Petrelintide works through a different pathway than GLP-1 drugs, activating the amylin receptor to promote satiety and improve leptin sensitivity.
Market Reaction
Despite the positive safety profile, analysts focused on the magnitude of weight loss, which fell below expectations set by several investigational drugs in the obesity pipeline.
Following the announcement, Zealand Pharma shares fell sharply, reflecting investor concerns about how the drug will compete in a market where higher weight-loss percentages have become the benchmark.
What Comes Next
Zealand Pharma and Roche plan to advance petrelintide into Phase 3 trials later in 2026, with additional studies evaluating its use in people with type 2 diabetes and in combination with other metabolic therapies.
If the Phase 2 results hold in larger trials, petrelintide could help address a persistent challenge in obesity treatment: finding therapies that patients can stay on long enough to realize their full benefits.
Sources
